Drug Profile


Alternative Names: Entyvio; Kynteles; LDP-02; LPD-02; MLN-0002; MLN-002; MLN-02

Latest Information Update: 27 Feb 2017

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Millennium; Takeda; Takeda Oncology
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Alpha4-beta7 integrin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Ulcerative colitis
  • Phase III Primary sclerosing cholangitis
  • Phase I Graft-versus-host disease; Malignant melanoma

Most Recent Events

  • 17 Feb 2017 Interim efficacy data from a phase III GEMINI LTS trial in Crohn's disease and Ulcerative colitis released by Takeda
  • 20 Dec 2016 Millennium Pharmaceuticals plans a phase II trial for Graft-versus-host disease (NCT02993783)
  • 12 Dec 2016 Launched for Crohn's disease in Austria, Denmark, Finland, Ireland, Poland, Slovenia, Sweden (IV) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top